Axsome Therapeutics (AXSM) Price & Analysis

Compare

2,198 Followers

AXSM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$72.21 - $139.13

Previous CloseN/A

Volume140.83K

Average Volume (3M)629.10K

Market Cap

$4.99B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Aug 04, 2025

EPS Estimate

-1.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.22

Shares Outstanding49,236,366

10 Day Avg. Volume644,907

30 Day Avg. Volume629,102

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$175.23

Price Target Upside70.09% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

Bulls Say, Bears Say

Bulls Say

Market ValuationAxsome shares are viewed as highly undervalued, with expectations of a string of catalysts over the coming months to support management's vision.

Regulatory ApprovalsThe company indicated that it expects 7 approvals by 2028, highlighting the late-stage development of many assets in the pipeline.

Sales PotentialAxsome Therapeutics has 5 Phase III development programs ongoing, with 7 potential approvals through 2028, driving peak sales potential of over $16 billion.

Bears Say

Regulatory ChallengesInvestors have expressed concern in Axsome's regulatory execution due to the FDA's recent refusal to file decision for AXS-14 in fibromyalgia.

Regulatory UncertaintyThe regulatory path forward for AXS-05 in Alzheimer's agitation is a major focus for investors, with optimism for approval and early adoption due to its solid tolerability profile.

Axsome Therapeutics News

Axsome Therapeutics hosts frontiers in Brain Health R&D Day

Axsome Therapeutics (AXSM) will host its Frontiers in Brain Health R&D Day in New York City to review...

12d ago

AXSM

AXSM Earnings this Week: How Will it Perform?

Axsome Therapeutics Inc. (AXSM) is scheduled to report 2nd quarter earnings on 08/04/2025, before the market opens. Regarding...

7h ago

AXSM

Optimistic Outlook for Axsome Therapeutics: Promising Pipeline and Potential Sales Growth Drive Buy Rating

Leerink Partners analyst Marc Goodman has maintained their bullish stance on AXSM stock, giving a Buy rating yesterday....

10d ago

AXSM

Axsome Therapeutics: Undervalued Stock with Promising Pipeline and Near-Term Catalysts

TD Cowen analyst Joseph Thome maintained a Buy rating on Axsome Therapeutics today and set a price target...

11d ago

AXSM

Axsome Therapeutics: Strong CNS Pipeline and Growth Potential Justify Buy Rating

Axsome Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

11d ago

AXSM

Buy Rating for Axsome Therapeutics: Late-Stage Pipeline and Growth Potential

Analyst Ami Fadia from Needham maintained a Buy rating on Axsome Therapeutics and keeping the price target at...

11d ago

AXSM

Axsome Therapeutics: Promising Growth Driven by Robust Pipeline and Strategic Fit

William Blair analyst Myles Minter has reiterated their bullish stance on AXSM stock, giving a Buy rating yesterday....

11d ago

AXSM

Axsome Therapeutics’ Promising Pipeline and Growth Potential Justifies Buy Rating

Morgan Stanley analyst Sean Laaman has maintained their bullish stance on AXSM stock, giving a Buy rating on...

12d ago

AXSM

Aptiv, IIPR, Huntington, PNC, Axsome Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($APTV) ), ( ($IIPR) ), ( ($HBAN) ), ( ($PNC)...

28d ago

PNC

APTV

Axsome Therapeutics assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of Axsome Therapeutics (AXSM) with an Overweight rating and $190 price target The firm...

1M ago

AXSM

Positive Outlook for Axsome Therapeutics Driven by Regulatory Progress and Commercial Success

Axsome Therapeutics (AXSM) has received a new Buy rating, initiated by Morgan Stanley analyst, Sean Laaman. Sean Laaman...

1M ago

AXSM

Axsome Therapeutics participates in Alzheimer’s, Brain Health Awareness Month

Axsome Therapeutics (AXSM) is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact...

1M ago

AXSM

Optimistic Buy Rating for Axsome Therapeutics Amid Promising Developments and Strategic Initiatives

Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and...

1M ago

AXSM

Axsome Therapeutics supports Migraine, Headache Awareness Month

Axsome Therapeutics (AXSM) recognizes Migraine and Headache Awareness Month alongside the Association of Migraine Disorders. In honor of...

2M ago

AXSM

AXSM FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest stock price was $72.21 and its highest was $139.13 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is $4.99B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Aug 04, 2025 which is in 2 days.

How were Axsome Therapeutics Inc’s earnings last quarter?

Axsome Therapeutics Inc released its earnings results on May 05, 2025. The company reported -$1.22 earnings per share for the quarter, beating the consensus estimate of -$1.351 by $0.131.

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -1.05.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 49,236,366 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Axsome Therapeutics Inc reported an EPS of -$1.22 in its last earnings report, beating expectations of -$1.351. Following the earnings report the stock price went up 3.814%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in AXSM

Axsome Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-282.16%

Trailing 12-Months

Asset Growth

9.33%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and delivering novel therapies for the management of central nervous system (CNS) disorders. Based in New York, the company aims to address unmet medical needs through its innovative drug candidates. Axsome's core products include therapies targeting conditions such as major depressive disorder, migraine, and narcolepsy, leveraging its expertise in CNS pharmacology and drug delivery technologies.

Axsome Therapeutics (AXSM) Earnings & Revenues

AXSM Earnings Data >

AXSM Company Deck

AXSM Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a positive outlook with strong revenue growth, successful product launches, and significant pipeline advancements. However, the company faces challenges in achieving profitability and navigating regulatory and market landscapes.Read More>

AXSM Stock 12 Month Forecast

Average Price Target

$175.23

▲(70.09%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"80":"$80","211":"$211","112.75":"$112.8","145.5":"$145.5","178.25":"$178.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$210.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":175.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$175.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$148.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[80,112.75,145.5,178.25,211],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.97,111.20307692307692,119.43615384615384,127.66923076923078,135.9023076923077,144.13538461538462,152.36846153846153,160.60153846153847,168.8346153846154,177.0676923076923,185.30076923076922,193.53384615384616,201.7669230769231,{"y":210,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.97,108.52846153846154,114.08692307692307,119.64538461538461,125.20384615384614,130.76230769230767,136.32076923076923,141.87923076923076,147.43769230769232,152.99615384615385,158.55461538461537,164.1130769230769,169.67153846153846,{"y":175.23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.97,106.43384615384615,109.89769230769231,113.36153846153846,116.82538461538462,120.28923076923077,123.75307692307692,127.21692307692308,130.68076923076922,134.14461538461538,137.60846153846154,141.07230769230767,144.53615384615384,{"y":148,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":81.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.86,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >